Pacira BioSciences, Inc. (NASDAQ:PCRX) Financial Performance and Competitive Landscape

Font: Financial Modeling Prep  • Mar 02, 2026

• Pacira BioSciences, Inc. (NASDAQ:PCRX) has a Return on Invested Capital (ROIC) of 1.74%, which is below its Weighted Average Cost of Capital (WACC) of 6.19%, indicating inefficiencies in capital utilization.
• PTC Therapeutics showcases a high ROIC of 37.39% against a WACC of 7.70%, leading to a ROIC to WACC ratio of 4.86, highlighting strong capital efficiency.
• Comparatively, Ultragenyx Pharmaceutical and Enanta Pharmaceuticals report negative ROICs, suggesting challenges in generating sufficient returns on their capital.

Pacira BioSciences, Inc. (NASDAQ:PCRX) is a pharmaceutical company that focuses on developing and commercializing non-opioid pain management and regenerative health solutions. The company's flagship product, EXPAREL, is used for postsurgical pain management. In the competitive landscape, Pacira faces peers like Supernus Pharmaceuticals, PTC Therapeutics, Ironwood Pharmaceuticals, Ultragenyx Pharmaceutical, and Enanta Pharmaceuticals.

In evaluating Pacira's financial performance, the Return on Invested Capital (ROIC) is a crucial metric. Pacira's ROIC stands at 1.74%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 6.19%. This indicates that the company is not generating returns that exceed its cost of capital, suggesting inefficiencies in capital utilization.

Comparatively, Supernus Pharmaceuticals has a negative ROIC of -0.31% against a WACC of 3.02%. This shows that Supernus is also struggling to generate returns above its cost of capital. On the other hand, PTC Therapeutics shines with a ROIC of 37.39% and a WACC of 7.70%, leading to a ROIC to WACC ratio of 4.86, indicating strong capital efficiency.

Ironwood Pharmaceuticals also demonstrates effective capital use with a ROIC of 21.34% and a WACC of 5.68%, resulting in a ROIC to WACC ratio of 3.76. In contrast, Ultragenyx Pharmaceutical and Enanta Pharmaceuticals have negative ROICs of -43.59% and -22.45%, respectively, with ROIC to WACC ratios of -9.48 and -3.53, indicating challenges in generating sufficient returns on their capital.

Among its peers, PTC Therapeutics stands out with the highest ROIC to WACC ratio, suggesting it is effectively using its capital to generate returns well above its cost. This positions PTC Therapeutics as a leader in capital efficiency, while Pacira BioSciences and others may need to reassess their capital strategies to improve financial performance.